Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
作者信息
Lebwohl Mark G, Leonardi Craig L, Mehta Nehal N, Gottlieb Alice B, Mendelsohn Alan M, Parno Jeff, Rozzo Stephen J, Menter Alan
机构信息
Department of Dermatology, Mount Sinai Hospital, New York, New York.
Central Dermatology and Saint Louis University School of Medicine, St Louis, Missouri.
出版信息
J Am Acad Dermatol. 2020 Feb;82(2):519-522. doi: 10.1016/j.jaad.2019.09.042. Epub 2019 Sep 26.
PMID:31563641
Abstract
摘要
Zotero 插件